Last updated: May 14, 2024
Sponsor: University Hospital, Bordeaux
Overall Status: Active - Recruiting
Phase
N/A
Condition
Multiple Sclerosis
Neurologic Disorders
Memory Loss
Treatment
3D OPTIMIZED WMN MPRAGE
Clinical Study ID
NCT05227092
CHUBX 2021/59
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients older than 18 years old
CIS or RRMS
Medullary symptomatology less than 6 months
With or without an objective lesion on a subsequent MRI scan
Signed the Informed Consent
Exclusion
Exclusion Criteria:
Pregnant or potentially pregnant women
Breastfeeding woman
Contraindications to MRI
Other diagnosis (Neuro-myelitis spectrum disease or Progressive Multiple Sclerosis)
Surgical history on the spinal cord or lumbar spine
Patient under legal protection
Study Design
Total Participants: 60
Treatment Group(s): 1
Primary Treatment: 3D OPTIMIZED WMN MPRAGE
Phase:
Study Start date:
August 02, 2023
Estimated Completion Date:
May 01, 2026
Study Description
Connect with a study center
CHU de Bordeaux
Bordeaux,
FranceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.